Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hubei Guangji Pharmaceutical Co (000952) Fair Value & Analysis

Healthcare · CN · Market cap 2.1B CNY

Price¥6.01
Fair Value¥8.48
Upside+41.1%
Quality93/100
Evidence: Medium Range ¥6.36 – ¥10.61

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Hubei Guangji Pharmaceutical Co (000952) currently trades at ¥6.01, while our model-based Fair Value estimate is ¥8.48 — implying the stock looks roughly 41.1% undervalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. It also exports its products. The company was founded in 1969 and is based in Wuxue, China.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -29% AbbVie Inc (ABBV) -42% Roche Holding (ROGN) -4% Merck & Co (MRCK34) -35% AstraZeneca PLC (A1ZN34) -31%

Frequently asked questions

Is Hubei Guangji Pharmaceutical Co (000952) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥8.48 versus a price of ¥6.01 — about +41% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 000952?
Our 21-model fair value for Hubei Guangji Pharmaceutical Co is ¥8.48 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥6.01.
What is the quality score of 000952?
Hubei Guangji Pharmaceutical Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.